Malaria vaccine Quilimmune - Antigenics
Alternative Names: Quilimmune-MLatest Information Update: 14 Dec 2000
At a glance
- Originator Antigenics; Instituto de Immunologia
- Developer Instituto de Immunologia
- Class
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Falciparum malaria
Most Recent Events
- 14 Dec 2000 Discontinued-I for Falciparum malaria in Colombia (Unknown route)
- 01 Dec 2000 Aquila Biopharmaceuticals has been acquired by Antigenics
- 12 Mar 1999 New profile, split from generic Malaria vaccine profile